An Act Concerning Drug Wholesalers, Manufacturers And Distributors.
Impact
If enacted, SB00828 will directly impact several sections of Connecticut's General Statutes, specifically those regulating the roles of wholesalers and manufacturers in the drug supply chain. It will mandate that all such entities obtain proper registrations, with annual renewal requirements enforced by the Commissioner of Consumer Protection. The bill's updates will harmonize state regulations with modern industry practices, potentially increasing efficiency in pharmaceutical distribution while ensuring compliance with safety and security protocols.
Summary
SB00828 aims to amend existing laws governing drug wholesalers, manufacturers, and distributors in Connecticut. The bill introduces definitions for new concepts such as 'virtual manufacturers' and 'virtual wholesale distributors', which categorize entities that manage the distribution of drugs and devices without taking physical possession of them. This legislative change is in response to the evolving landscape of drug supply chains that include logistics providers and virtual operations, enhancing the clarity and governance of these entities under state law.
Contention
Some stakeholders may raise concerns regarding the implications of broadening the definitions and responsibilities for drug distributors. Critics may argue that the addition of 'virtual' entities could lead to regulatory challenges and complicate enforcement, suggesting that these definitions might create loopholes that undermine consumer protection and drug availability. However, supporters argue that these changes will modernize and streamline regulations, ultimately benefiting the healthcare system by improving access to a more organized and compliant distribution network.
Providing price limits and other requirements for health benefits covering prescription insulin drugs and establishing the insulin affordability program for the uninsured.